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Summary
As humans evolved, perhaps the two strongest selection determinants of survival were a robust
immune response able to clear bacterial, viral, and parasitic infection and an ability to efficiently
store nutrients to survive times when food sources were scarce. These traits are not mutually
exclusive. It is now apparent that critical proteins necessary for regulating energy metabolism such
as peroxisome proliferator-activated receptors (PPARs), Toll-like receptors (TLRs), and fatty
acid-binding proteins (FABPs) also act as links between nutrient metabolism and inflammatory
pathway activation in immune cells. Obesity in humans is a symptom of energy imbalance: the
scale has been tipped such that energy intake exceeds energy output and may be a result, in part,
of evolutionary selection toward a phenotype characterized by efficient energy storage. As
discussed in this review, obesity is a state of low-grade, chronic inflammation that promotes the
development of insulin resistance and diabetes. Ironically, the formation of systemic and/or local,
tissue-specific insulin resistance upon inflammatory cell activation may actually be a protective
mechanism that co-evolved to repartition energy sources within the body during times of stress
during infection. However, the point has been reached where a once beneficial adaptive trait has
become detrimental to the health of the individual and an immense public health and economic
burden. This article reviews the complex relationship between obesity, insulin resistance/diabetes,
and inflammation, and while the liver, brain, pancreas, muscle, and other tissues are relevant, we
focus specifically on how the obese adipose microenvironment can promote immune cell influx
and sustain damaging inflammation that can lead to the onset of insulin resistance and diabetes.
Finally, we address how substrate metabolism may regulate the immune response and discuss how
fuel uptake and metabolism may be a targetable approach to limit or abrogate obesity-induced
inflammation.
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Obesity and Inflammation, an Introduction
Over the past 20 years, the prevalence of obesity in the United States, and worldwide, has
reached epidemic proportions (1). In the United States, the most recent National Health and
Nutrition Examination Survey (NHANES) reported that 68.3% of individuals studied were
overweight, as defined by having a Body Mass Index (BMI, kilograms/meter2) of at least 25.
Over a third of the people surveyed were obese (BMI of at least 30) (1). Nineteen percent of
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U.S. children ages 6–11 years of age are overweight, as defined by being over the 95th
percentile for their age in BMI (2). Globally, the World Health Organization estimates 500
million adults and almost 43 million children under the age of 5 years are obese (3). The
pathogenesis of obesity is influenced by the elaborate interactions among a complex web of
factors including inherited genetic traits, behavioral, physical, or psychological factors,
environmental characteristics such as access to and availability of food sources, cultural
identity, education level, and socioeconomic status (4).
Obesity is associated with a constellation of pathologies that together are defined clinically
as the Metabolic Syndrome. The salient features of Metabolic Syndrome include insulin
resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, hyper-
coagulatablility, hypertension, and, of course, obesity, particularly central adiposity defined
as a waist:hip ratio of greater than 0.90 for men and 0.85 for women (5). The concurrence of
any three of these conditions will result in a diagnosis of Metabolic Syndrome. An in-depth
discussion of insulin resistance is beyond the scope of this review; however, in the pre-
diabetic state, insulin resistance occurs when the biological function of the insulin hormone
signaling cascade is blunted in metabolically sensitive tissues. Physiologically, insulin
resistance manifests as decreased insulin-stimulated blood glucose uptake by adipose and
skeletal muscle and a failure to inhibit glucose production by the liver and triacylglyceride
lipolysis and non-esterified free fatty acid (NEFA) release from adipose stores (6). The
impaired insulin function may be temporarily alleviated through compensatory increases in
islet β cell number and size aimed at boosting insulin production in an effort to overcome
the insulin signaling impairment. Hyperinsulinemia can compensate for the lack of insulin
sensitivity for a time; however, overtaxing β cells is not a permanent solution. Overworked
β cells will eventually fail, ultimately resulting in insulin insufficiency in susceptible
patients or mouse models (6).
The combined effects of insulin resistance can lead to the development of hyperglycemia
and hyperlipidemia that may progress to the point at which an individual is diagnosed with
Type 2 diabetes mellitus (referred to as ‘Type 2 diabetes’ throughout this review), a
condition tightly associated with obesity. This is in contrast to Type 1 diabetes mellitus, an
autoimmune disease that typically afflicts children and is characterized by a lack of
pancreatic insulin production due to immune-mediated ablation of β cells (7, 8). About 90–
95% of diabetes cases are individuals with Type 2 diabetes and an estimated 25.8 million
people have been diagnosed with Type 2 diabetes in the United States. Epidemiologists
predict that Type 2 diabetes may affect as much as 33% of the United States population by
2050 (9). Diabetes is also a worldwide epidemic with the WHO predicting a doubling of
diabetes-related deaths from 2005 to 2030, with poorer countries suffering the greatest
burden (3).
Obesity, characterized as a state of low-level inflammation, is a powerful determinant
influencing the development of insulin resistance and progression to Type 2 diabetes (10,
11). Two seminal manuscripts published in the Journal of Clinical Investigation in 2003 (12,
13) brought to light a new understanding of the role of adipose inflammation, particularly
macrophage-mediated inflammation, in obesity. The results of the experiments described in
these papers demonstrated that macrophages infiltrate adipose tissue at the onset of weight
gain and directly contribute to and perpetuate the inflammatory state of fat, eventually
leading to systemic insulin resistance and the development of obesity in both mouse models
and humans (12, 13). Indeed, there is a 4-5-fold increase in adipose tissue macrophage
content from the lean to the obese state with macrophages constituting up to 50% of the cells
present in obese adipose (14). Although this process is still unclear, macrophages likely
infiltrate adipose in response to a ‘stress’ signal emanating from the adipocyte, with larger,
more insulin resistant adipocytes in obesity suffering the most stress (15, 16). Macrophage
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quantities are highly correlated with adipocyte size, as well as age, female gender, and the
expression of numerous inflammatory markers (14, 17–23). Obesity and Metabolic
Syndrome are currently and will continue to be significant public health concerns
worldwide; therefore, there is a pressing need for the development of a deep understanding
of the relationships between obesity, inflammation, and metabolism.
Obesity-associated inflammation contributes to the development of insulin
resistance
Work over the past decade has increasingly linked obesity and inflammation. Contrary to an
acute response to an injury such as a laceration that we normally associate with
inflammation, which would typically induce pain and swelling, to be soothed with a bandage
and antibiotics to ease the insult, obesity-associated inflammation is a chronic, unmitigated,
inflammation with insidious results (20, 24–27). Cytokines, reactive oxygen species (ROS),
and other agents produced by immune cells and adipocytes are released that can activate
important stress pathways and disrupt critical metabolic processes implicated in obesity such
as the insulin signaling cascade (Fig. 1A).
Almost 20 years ago, Hotamisligil et al. (28) reported the first evidence that adipose tumor
necrosis factor-α (TNFα), a pro-inflammatory cytokine, has the ability to disrupt the insulin
signaling cascade (Fig. 1B). More recently, Weisberg et al. (12) used a macrophage-depleted
bone marrow transplant model system to demonstrate that adipose macrophages are the
source of the majority of the TNFα expressed in this tissue and that bone marrow-derived
macrophages are necessary for supporting an obese phenotype. Furthermore, animals
lacking macrophage chemotactic protein-1 (MCP-1, Ccl2) or its receptor Ccr2, the ligand
and receptor classically associated with macrophage trafficking, are characterized by
decreased macrophage infiltration into adipose, decreased susceptibility to systemic insulin
resistance and obesity (14, 15, 29).
Since then, it has become accepted that obesity-associated inflammation contributes to
insulin resistance and the inflammatory nature of the adipose microenvironment continues to
be an active area of research. Inflammatory mediators including IL1-β, IL-6, IL-8, IL-10,
transforming growth factor-β (TGFβ), TNFα, MCP-1 (CCL2), plasminogen activating
inhibitor-1 (PAI-1/Serpine), macrophage migratory inhibitory factor (MIF), metallothionine,
osteopontin, chemerin, and prostaglandin E2 (PGE2) are just a few bioactive mediators
secreted from obese adipose (10, 30–34). Interestingly, the adipose stromal vascular
fraction, which contains primarily nonfat cells including macrophages, may play a more
prominent role in the development of obesity-associated inflammation and insulin
resistance, as cells in this fraction tend to secrete levels of inflammatory mediators
exceeding those excreted by adipocytes (35).
Adipose microenvironment
What role are adipocytes, macrophages and other immune cells playing in the progression of
obesity and insulin resistance? Monocyte trafficking and activation are well-characterized
aspects of atherosclerosis that may offer some clues as to the function of immune cells in
obese adipose (36). Extensive research focused on monocyte trafficking in atherosclerotic
lesions demonstrates that macrophage infiltration of the blood vessel wall, subsequent
uptake of oxidized lipoprotein, and the resultant pro-inflammatory response are central
components involved in the formation of cholesterol-laden foam cells and expanding
atherosclerotic plaques (37–43). Similarly, as obesity progresses, immune cells infiltrate
either transiently (neutrophils) or continuously over time (innate and adaptive cells) while
other beneficial immune cells decrease in number or are functionally overshadowed (Fig. 2).
Johnson et al. Page 3













As macrophages disperse into adipose tissue and accumulate triglycerides, they become
activated and subsequently cause tissue damage in a fashion reminiscent to the formation of
an atherosclerotic lesion (12, 13, 44). Therefore, lessons may be learned from considering
other immune-linked metabolic diseases like atherosclerosis, which can be applied to the
obese adipose microenvironment: the prime lesson being to focus on the complexity of cell-
cell interactions rather than the tissue as a whole.
Adipocytes
The adipocyte is obviously the cell best studied in adipose biology with much work focused
on adipocyte differentiation and triglyceride droplet formation. Once thought to be a static
storage depot for calories as triglycerides, adipose tissue is now considered to be an
endocrine organ with an important role in local and systemic homeostasis. It has been
demonstrated that adipose has the ability to secrete many hormones derived from
adipocytes. These hormones include cytokines and chemokines called ‘adipokines’ or lipid
mediators recently termed ‘lipokines’. These molecules function as either systemic,
paracrine, or autocrine hormones. Leptin, the classic adipokine first discovered by
Friedman’s group (45), is primarily secreted by adipocytes. As adipocytes grow and
accumulate triglyceride, circulating leptin concentrations increase proportionally; therefore,
leptin concentration is an indicator of adipose mass. In an effort to maintain metabolic
homeostasis, leptin negatively regulates appetite, drives physical activity, and promotes
insulin sensitivity. However, chronically elevated levels of leptin in the obese results in a
state of central leptin resistance, ultimately limiting satiety cues (reviewed in 46).
Adiponectin is another well-known adipokine that is regulated inversely to leptin. In contrast
to leptin’s expression, adiponectin production becomes blunted with increasing adiposity
(47). Adiponectin promotes insulin sensitivity (48, 49) and is anti-inflammatory (50–52).
Indeed, low adiponectin level is associated with Metabolic Syndrome (53).
In contrast to leptin and adiponectin, several adipokines have been shown to promote insulin
resistance. Resistin, which is secreted mainly from adipocytes in rodents but primarily by
macrophages in humans, has been demonstrated to induce insulin resistance (54–56).
Retinol-binding protein 4 (RBP4) (57) and angiotensinogen (58, 59) are examples of other
adipokines that have been linked to the development of insulin resistance and inflammation.
Hyper-coagulation is another hallmark of Metabolic Syndrome and there is evidence that
adipose tissue is responsible for the secretion of several acute phase proteins involved in the
inflammation and thrombosis linked to Metabolic Syndrome including serum amyloid A
(SAA), PAI-1, and CRP (60–64). Adipose tissue is also a source of angiogenic mediators
such as vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2),
matrix metalloproteinase-9 (MMP-9), and hepatocyte growth factor (HGF) (35). Together,
these adipokines, chemokines, and cytokines constitute a complex network of pro- and anti-
inflammatory regulatory mediators.
In addition to secreted proteins, lipids are also released that act locally and systemically. In a
lean state, insulin signaling inhibits lipolysis and NEFA release from adipocytes. However,
limited insulin responsiveness in obese adipocytes results in reduced attenuation of lipolysis
and subsequently elevated levels of circulating NEFAs. NEFAs play a large role in the
lipotoxic effect associated with inflammation (discussed below). Additionally, certain
oxidized NEFA species function as bioactive lipid mediators, or lipokines, such as the
eicosanoids prostaglandin D2 (PGD2) and its derivative prostaglandin J2 (PGJ2), have been
shown to be relevant mediators of leptin and adiponectin release (65, 66). In addition, a
recent publication reported that palmitoleic acid drives improvements in insulin sensitivity
systemically and several epidemiologic studies support this notion (67–69). Why do we see
these drastic changes in adipokine and lipokine secretion from obese adipose tissues in
humans and animal models? Various mechanisms including hypoxia and oxidative stress are
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addressed in this review, but one must first comprehend the entirety of the adipose
microenvironment, which includes considering the dynamics of stromal constituents in
obesity, especially the migration of immune cells such as macrophages, lymphocytes, and
other granulocytes.
Macrophages
In addition to the adipocyte, the microenvironment of adipose consists of many other cells
central to the health of the tissue that are involved in pathogenesis of obesity. These cell
types include pre-adipocytes, endothelial cells, fibroblasts, and immune cells; while this
review is focusing on the latter, it does not preclude the importance of other stromal
constituents (reviewed in 70). As mentioned above, the bone marrow-derived macrophage
was the first immune cell shown to be highly relevant to adipose biology and is the most
investigated (12, 13, 71, 72). However, the adipose stromal microenvironment is far more
complex; macrophages are not just one simple cell type but rather can exist displaying a
range of phenotypes or subtypes, can be resident or infiltrating, and perform different
functions depending on tissue localization (73). Broadly speaking, ‘M1’ macrophages are
pro-inflammatory, activated via the classical pathway wherein type 1 T-helper (Th1)
inflammatory cytokines interferon γ (IFNγ) and TNFα are induced by agents such as
cytokines, infections, or saturated fatty acid stimulation (74–77) (Fig. 3). In contrast, ‘M2’
macrophages are activated by type 2 T-helper (Th2) cytokines IL-4 and IL-13 (78, 79). M2
or alternatively activated macrophages are found to be resident cells in adipose tissue from
lean individuals and are thought to be involved in remodeling and tissue repair through the
production and expression of IL-10, IL-1 receptor antagonist, and arginase-1 (75, 80–83).
Different macrophage subtypes have been shown to modulate inflammation-associated
insulin resistance in metabolic tissues such as adipose and liver. Indeed, manipulation of the
macrophage population can ameliorate or worsen pathology (75, 80, 84).
As an individual becomes increasingly obese, there is a dramatic increase in M1
macrophages into adipose tissue. As lipid accumulation continues, both in adipocytes and
macrophages within the adipose tissue, there is a shift in macrophage subtype to a pro-
inflammatory, M1 polarization (75, 76, 84–86). In obese adipose, chronic inflammation
ensues with pro-inflammatory release of TNF-α, IL-1β, PAI-1, and ROS (12, 13, 15, 35).
Lumeng et al. (75, 84) demonstrated that M2 macrophages are dispersed in adipose tissue,
whereas infiltrating M1 macrophages form ‘crown-like structures’ around dying adipocytes
(Fig. 2B). Through the use of genetic alteration and bone marrow transplant models, M2
‘anti-inflammatory’ macrophages are demonstrated to maintain insulin sensitivity in liver
and adipose, while M1 macrophages have been shown to inhibit insulin sensitivity, which
can lead to systemic insulin resistance and the promotion of an ‘obesogenic’ inflammatory
microenvironment (80, 87, 88). In addition to subtype, location of adipose tissue is highly
relevant to the inflammatory response with visceral (fat including gonadal fat pads,
omentum, and other fat surrounding the viscera) being more inflammatory than
subcutaneous adipose underlying skin (89). Interestingly, obesity-induced macrophage
infiltration also occurs in the normal breast mammary gland, a large fat pad (90), suggesting
that immune cell-mediated inflammation is not restricted to subcutaneous and visceral
depots.
The role of fuel substrate metabolism in macrophage subtype polarization
While categorizing M1 vs. M2 subtypes is convenient for in vitro purposes, in vivo studies
demonstrate that there is, in actuality, a vast spectrum of macrophage subtypes with some
plasticity rather than solely M1- or M2-polarized (91) (Fig. 3). Indeed, the macrophage
subtype may be molded by the microenvironment in which the cell is present or systemic
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characteristics of the organism. To date, the mechanisms influencing plasticity of M1 and
M2 macrophages remains a hotly debated topic.
One potential modifier of plasticity is the availability of fuel substrates to the macrophages
in the microenvironment. For example, macrophage phenotype may be shaped by the
availability of excess glucose characteristic of hyperglycemia in diabetes or elevated fatty
acids as is the case with hypertriglyceridemia or uncontrolled lipolysis in the obese state.
Vats et al. demonstrated that M1 macrophages tend to utilize the glycolytic pathway for
energy generation, while M2 macrophages may prefer β-oxidation of fatty acids as fuel (80,
92, 93). M2 macrophage polarization is dependent upon the transcription factors PPARδ and
γ as well as the co-activator PGC1β, known to promote mitochondrial biogenesis and fatty
acid β-oxidation (92). In monocytes/macrophages lacking the nuclear hormone receptors
PPARδ or γ, PGC1β, or when treated with etomoxir, the pharmacological inhibitor of
carnitine palmitoyltransferase 1 (CPT1) which blunts long chain fatty acid uptake into
mitochondria and therefore β-oxidation, cells cannot be polarized to the M2 phenotype and
display M1 characteristics (92). Although there are high levels of M2-polarizing lipids
released from the adipose in an obese state, the coordinated changes of cytokine production
and immune cell populations as adiposity increases results in an inflammatory
microenvironment favoring an M1 phenotype. Furthermore, when one considers the
metabolism of a single amino acid, it becomes evident how important metabolites are to the
immune response. IL-4 activation of the stat6/PPARγ pathway acts to increase transcription
of arginase 1, an enzyme characteristic of M2-polarized macrophages. Arginase 1
metabolizes L-arginine to L-ornithine (and urea) as the last step in the urea cycle. The end
product ornithine can be modified through a glutamic semialdehyde intermediate to proline,
a necessary amino acid in the synthesis of collagen (94), supporting the role for M2
macrophage in tissue remodeling. In contrast, in M1 macrophages arginine is used for the
generation of a completely different end product – the reactive oxygen species nitric oxide
via the catalytic activity of nitric oxide synthase. The expression of nitric oxide synthase is a
hallmark of pro-inflammatory M1 macrophage (76). As the inflammatory state of
macrophages may be inherently linked to a preference for a single energy-producing
pathway or relevant metabolite over another in these cells, regulating the fuel substrate
usage by macrophages is one potential means for manipulation of the inflammatory
response, to be discussed further below.
B and T-lymphocytes in adipose inflammation
Most work on obesity and inflammation has focused on macrophage infiltration and
activation in the adipose. However, recent reports have demonstrated unique roles for a
variety of immune cells in the adipose, including cells from both innate and adaptive arms of
the immune system. Similar to macrophages, B cells and T cells play dynamic roles in the
transition from metabolic homeostasis in lean adipose to a state of chronic inflammation and
insulin resistance in the obese (95–97) (Fig. 2).
B and T lymphocytes can influence obesity and insulin resistance. B lymphocytes have been
shown to infiltrate adipose with onset of weight gain (98) and contribute to insulin resistance
(99) but have been studied to a much lesser extent then adipose-resident T cells. T cells were
first identified in visceral fat, and secretion of Th1 cytokines was shown to regulate adipose
inflammation. Importantly, appearance of T cells was proximal to induction of insulin
resistance (98, 100–104). T cells infiltrate adipose early in the development of obesity, prior
to a major influx of macrophages (98). Interestingly, in Rag2−/− mice, which lack mature B
and T cells, there is an increase in natural killer (NK) cells and macrophages in adipose
suggesting that early infiltration of B and T cells may be necessary for inflammatory
suppression in this tissue (98). However, one publication (105) suggested that T cells were
not involved in insulin resistance despite elevation of some cytokines.
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Contradictory findings highlight the complexity of T-cell biology, again underscoring that
populations and subtypes must be considered when studying obesity and inflammation. For
instance, it is well known that CD4+ Th1 cytokines, such as regulated on activation, normal
T cell expressed and secreted (RANTES) and IFNγ, drive inflammation and polarization of
macrophages towards the M1 phenotype in fat and liver in obesity (103, 104, 106). Light
was shed upon adipose T-cell complexity through the study of CD4+ T-regulatory cells
(Tregs) subtype. Tregs are anti-inflammatory tolerogenic lymphocytes, typically associated
with allergic reaction, that secrete Th2 cytokines such as IL-4 and IL-13. Indeed, Tregs play
an integral role in preventing adipose inflammation and insulin resistance (107). Tregs are
found in lean adipose and decrease with increasing obesity, as do CD4+ Th2 cells (99, 106).
In contrast, CD8+ and CD4+ Th1 cells increase with obesity, and CD8+ T cells were shown
to contribute to macrophage recruitment in obesity (108). Immunotherapy aimed at blunting
Th1 cells using CD3-specific antibody or its F(ab′)(2) fragment or acutely depleting adipose
of T cells was shown to normalize adipose inflammation and insulin sensitivity in mice (99,
109, 110). Finally, there are also depot-specific differences in lymphocyte populations,
which support other immune cell-mediated findings in terms of inflammation, diabetes, and
obesity (111). O’Rourke et al. (112) demonstrated the relevance of lymphocytes in visceral
adipose, relative to subcutaneous adipose, which was characterized by elevated T and
natural killer (NK) cells, elevated IFN-γ, and greater activation of TNFα secretion from
macrophages.
In sum, the accumulation of inflammatory cells, such as CD8+ T cells and Th1 cells, and the
relative decline in anti-inflammatory Th2 cells and Tregs account for skewing the adipose
towards an inflammatory state and drive macrophage polarization towards an M1 phenotype
(Fig. 2). Much remains unknown about T-cell biology in adipose tissue, including timing
and localization of interactions among cell types with regard to cytokine, hormone, and
other substrate exposures within the adipose. Indeed, similar to macrophage fuel
metabolism, T-cell subtype skewing occurs through modulation of substrate metabolism
regulated by cytokines and hormones, such as leptin and intracellular nutrient sensing
kinases such as protein kinase B (PKB/AKT), liver kinase B1 (LKB1), AMP-activated
protein kinase (AMPK), and mammalian target of rapamycin (mTOR), among others (113–
119). However, little is known about how the obese state modulates T-cell metabolism.
Interestingly, obese mice and humans have altered memory T-cell responsiveness (120,
121). The question arises: is there a link between obesity altering T-cell metabolism and thus
function? Taken together, B and T-cell populations in adipose tissue must not be overlooked
when considering obesity-induced inflammation.
Other immune cells
The factors driving adipose inflammation are likely multiple and involve complicated
relationships among varied signaling molecules. Indeed, essentially all other hematopoietic
cells have been identified in obesity-associated inflammation in addition to macrophages
and lymphocytes (122). Natural killer T (NKT) cells have been shown to be necessary and
sufficient to drive obesity-induced inflammation through invariant NKT deficiency and
agonist studies (123–125). In contrast, a recent publication has suggested that NKT cells
behave in the opposite manner, as a protective mechanism through secretion of Th2 M2-
polarizing cytokines, thus improving insulin sensitivity. This group further showed that
NKT cells decrease with increasing adiposity and insulin resistance (126). In addition, a
subset of NK cells (not NKT cells) was also recently identified by Moro et al. (127) that
express c-Kit and Sca-1 and are located in what they term ‘fat-associated lymphoid cluster’
(FALC). This subset of NK cells also secretes Th2 cytokines and maintains insulin
sensitivity. Clearly, further characterization of NKT and NK cell subsets, relevant signaling
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molecules, and biologic activity of these cells need to be further clarified in a manner similar
to understanding the role of differentially polarized macrophages in obesity.
Mast cells, primary mediators of allergic reactions, have been implicated in obesity and
insulin resistance through the use of animal models of mast cell activation and dysfunction
(128). Furthermore, it has been demonstrated that mast cells can modulate lipogenesis via
paracrine action of the eicosanoid 15-deoxy-delta-12, 14-PGJ2 (129). In fact, obese humans
and mice have an overall increased burden of mast cells (128) and adipose tissue has been
identified as a source of mast cell progenitor cells (130), suggesting a synergistic
relationship between adipose tissue and mast cell propagation. Therefore, it is reasonable to
expect that obesity-induced mast cell propagation may be a driver of allergic diseases such
as asthma (131).
Other granulocytes have also been shown to be relevant to the immune response in adipose.
Elgazar-Carmon et al. (132) demonstrated that after just three days of high fat feeding,
neutrophils infiltrate adipose tissue. In humans, neutrophils were positively associated with
Metabolic Syndrome (133). Basophils are the rarest granulocyte and the relationship
between these cells and obesity-associated outcomes is less clear. Epidemiologic data are
conflicting: while two human studies found non-statistically significant elevations in serum
basophils with obesity, two studies found a positive relationship between circulating
basophils and either BMI or markers of Metabolic Syndrome (134–137). Although leptin
has been shown to regulate basophil migratory response and survival (134), to date, there are
no reports of investigations examining basophil infiltration in obese adipose or direct
relationship between basophils and insulin resistance.
Unlike other granulocytes, eosinophils have been shown to play a protective role against the
formation of obesity and insulin resistance through blunting adipose inflammation.
Eosinophil numbers decrease with obesity and have been shown to be essential to
maintaining the macrophage M2 phenotype and insulin sensitivity in vivo. In fact, an
interesting experiment by Wu et al. (138, 139) utilized parasitic infection to induce
eosinophil activation and improved insulin resistance in mice. Clearly, the role of these
lesser studied granulocytes should be further investigated. Taken together, adipose
inflammation is a complex interaction of acute innate responses, adaptive immunity, and the
loss or maintenance of chronic adaptive and innate cell populations that together act to
perpetuate and exacerbate adipose inflammation.
The challenge of characterizing the adipose microenvironment
As discussed above, adipose tissue is not simply composed of adipocytes. Therefore, to
thoroughly study chronic inflammation in this tissue, one must consider the complexity of
the adipose microenvironment. As one of the largest endocrine organs in the body, adipose
is responsible for the production and release of many potent signaling molecules including
adipokines, lipokines, and inflammatory mediators that may elicit effects both locally and
systemically. The inflammatory state of the adipose tissue regulates the identity and
concentration of these released molecules. It has taken some time to clarify the relative
contributions of as well as the interactions among the various cell types contained within the
microenvironment to the development of obesity-induced insulin resistance. To achieve this,
several technological hurdles needed to be overcome.
Immunohistochemistry, a standard technique used to determine the expression level and
localization of proteins in tissues, is a challenge in adipose tissue, because the immense
triglyceride droplet contained within the adipocyte forces the nucleus and other organelles to
be pushed to the perimeter of the cell. Therefore, it is difficult to distinguish the boundaries
of neighboring adipocytes. Partitioning of adipose-enriched versus stromal vascular
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fractions for flow cytometry, quantitative polymerase chain reaction (PCR) or Western blot
analysis is fraught with technical difficulties. Digestion with enzymes such as collagenase
must be sufficiently rigorous to dissociate immune cells from adipocytes to avoid cross-
fraction contamination, as the stromal vascular fraction contains many cells types (including
pre-adipocytes, macrophages, T cells, endothelial cells, among others), while at the same
time be gentle enough so as not to destroy or damage the adipocyte. Flow cytometry of
adipocytes from dissociated tissue is difficult due to the delicate nature of the adipocyte; on
the other hand, the stromal vascular fraction can be readily characterized by separation of its
cell types through the use of fluorescence-activated cell sorting (FACS) or cell isolation kits
(84). Finally, in vivo adoptive bone marrow transplant or cell transfer studies are techniques
commonly used to study obesity-induced inflammation. Therefore studies in vivo, in
combination with ex vivo culture of primary cells or, alternatively, co-culture techniques
using primary or established cell lines, are necessary to attempt to model and characterize
the complex microenvironment in adipose.
Genetic loss-of-function studies are often used to study the adipose microenvironment using
Cre-flox technologies to achieve tissue or cell type-specific gene knockdown in animals. In
the past, many studies employed the use of what was thought to be an adipocyte-specific
promoter for the fatty acid binding protein aP2/FABP4 gene; however, work by our group
and others demonstrated that aP2 is present in activated macrophages as well as other cells,
and this protein is relevant for many immune-mediated responses including insulin
resistance, atherosclerosis, experimental allergic encephalomyelitis (EAE), and asthma (26,
140–143). An alternative to the aP2 promoter is the promoter for adiponectin that allows for
adipocyte specific expression of Cre recombinase (144). To study immune cells, lysosomal-
M (LysM)-Cre is an excellent tool for targeted gene deletion in cells of the monocyte/
macrophage lineage and is used often in studying obesity-induced inflammation. One caveat
is that LysM-Cre is also expressed in microglia (brain macrophages) (145). The role of
neural alterations impacting appetite, energy expenditure, and feeding behavior regulation
stemming from gene deletion in microglia is a critical, often overlooked aspect of the
development of obesity and insulin resistance (146). While the heterogeneous nature of
adipose is complex, the variety of experimental approaches makes the study of macrophage
and other immune cell biology in adipose inflammation an attractive field.
Mechanisms of inflammatory activation
As is the case with other aspects pertaining to the pathogenesis of obesity, the mechanism
regulating the activation of obesity-associated inflammation is multifactorial. As alluded to
above, we posit that nutrient metabolism plays an immense role in shaping the immune
response in adipose tissue. With a focus on the macrophage, the role of glucose and
glucotoxicity, fatty acids and lipotoxicity, as well as stress kinases, ER stress, and
inflammasome activation on macrophage polarization will be addressed.
Immune cells express pattern recognition receptors (PRRs) specific for pathogen-associated
molecular patterns (PAMPs), which allows for induction of a rapid inflammatory response.
Bacterial component lipopolysaccharide (LPS) is a ligand for Toll-like receptor 4 (TLR).
TLR4 activation through LPS results in activation of cell-signaling pathways that ultimately
result in the production of pro-inflammatory cytokines, such as TNFα. Interestingly, TLR4
can be activated through saturated fatty acids, as there is a degree of similarity in structure
among LPS and saturated fatty acids (147) (Fig. 1B). In addition, binding of cytokines to
plasma membrane receptors or intracellular lipid mediators such as diacylglyceride (DAG)
can initiate inflammatory signaling pathways. Regardless of the inflammatory stimulus, a
variety of kinases link extracellular stress signals with intracellular production of
inflammatory molecules. Over 500 different kinases have been identified (148), some of
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which are directly involved in mediating inflammatory activation. Stress kinases associated
with inflammatory activation in adipose include the DAG-activated protein kinase C (PKC)
(149–152), mitogen-activated protein kinase (MAPK) pathway members including c-Jun N-
terminal kinase (JNK) (153–156), extracellular signal-regulated kinase (ERK) (157, 158),
p38 MAPK (153, 159), as well as inhibitor of κB (IκB) kinase (IKK) (17, 160, 161). JNK
and IKK activate transcription factors integral to inflammation, such as activator protein 1
(AP1), c-Jun/Fos, and nuclear factor-κB (NFκB). Importantly, in addition to activating
typical inflammatory responses, activation of these kinases has been linked to inhibition of
insulin signaling. For instance, JNK and IKK are serine kinases that have been shown to
phosphorylate and inhibit the insulin receptor substrate 1 (IRS-1) via phosphorylation of
serine residues, thus blunting the insulin signaling cascade (155) (Fig. 1B). Further, JNK and
IKK signaling also results in activation of transcription factors integral to inflammation,
such as AP1, c-Jun/Fos, and NFκB.
Through the use of genetic knockout models, pharmacologic treatments and studies in
humans, it has become clear that the actions of inflammatory kinases such as JNK and IKK
play central roles in both obesity and insulin resistance (17, 77, 154–156, 160–167).
However, decreased inflammatory kinase activity achieved through genetic manipulation in
mouse models does not necessarily result in decreased obesity. Despite the fact that many
models with JNK or IKK inhibition display increased lipid accumulation in liver and
skeletal muscle, animals with absent or blunted stress kinase activation remain insulin
sensitive (17, 166), demonstrating that while adiposity and triglyceride accumulation are a
harbingers of inflammation and insulin resistance, lipid accumulation per se is not always
linked to insulin resistance: activation of inflammatory response is paramount. There are
several links between substrate metabolism, kinase activation, and the pro-inflammatory
response included in states of glucotoxicity and lipotoxicity.
Glucotoxicity and obesity-induced inflammation
High glucose exposure is known to drive the pro-inflammatory activation of macrophages
potentially through multiple major pathways including the production of reactive oxygen
and nitrogen species (namely, oxidative burst and endogenous production), alterations in
cellular redox potential, activation of TGFβ-stimulated release of pro-inflammatory
cytokines, and glucose-induced lipotoxicity.
Upon activation, macrophages classically demonstrate a ‘respiratory burst’ when attacking
an offending bacterium (reviewed in 168) and significantly increase glucose uptake to allow
for production of metabolites necessary to kill the pathogen through generation of reactive
oxygen and nitrogen species. The respiratory burst is initiated by activation of the
phospholipase C-mediated release of DAG and inositol triphosphate (IP3) following
extracellular macrophage stimulation. Next, Ca2+ is released from the endoplasmic
reticulum, which leads to activation of PKC, the kinase responsible for the phosphorylation
of NADPH oxidase subunits, particularly p47phox (149). NADPH oxidase is fully assembled
and subsequently translocated to the cellular plasma membrane. NADPH oxidase catalyzes
the conversion of extracellular oxygen to superoxide (O2·−) which can be utilized by
macrophages to kill invading pathogens or may be dismuted into hydrogen peroxide (H2O2)
and oxygen (169). The respiratory burst is often called a ‘glycolytic burst’ due to the
increase in glucose uptake. Macrophages express glucose transporters GLUT1, 3 and 5, with
GLUT1 being the primary transporter. GLUT1 expression is increased with macrophage
activation (170–173, authors’ unpublished observations).
Similar to a pathogenic response to an invading bacterium, excess nutrients found in the
obese adipose microenvironment can lead to the pro-inflammatory activation of
macrophages. Chait and colleagues (174–177) have extensively studied the links between
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glucose and ROS production in obesity and have published data demonstrating that elevated
glucose exposure drives inflammation and adipose tissue macrophage infiltration. Activation
of the main enzyme involved in the respiratory burst, NAPDH oxidase (also known as
NOX4), ROS production, and pro-inflammatory chemokine MCP-1 release were shown to
be dependent upon glycolysis and the pentose phosphate pathway of glucose metabolism
(178, 179). In addition, excessive glucose availability, in conjunction with high LDL
exposure also resulted in elevated NADPH oxidase activity, H2O2 production, and
chemotaxis in monocytes (180). Therefore, glucose uptake and metabolism drives ROS
production and inflammation.
Second, endogenous production of ROS is a physiologic aspect of metabolism. The
mitochondrial electron transport chain is the primary site for the production of ROS. ROS
production is accelerated when the flow of electrons through the electron transport chain is
impaired or when the constituents of the electron transport chain remain in a reduced state
(181). In cells with elevated exposure to and uptake of glucose, the electron transport chain
is hyperpolarized and produces excessive ROS (182). ROS, specifically H2O2, can also
signal intracellularly in a physiologic manner (183) within macrophages, leading to
enhanced activation of well-known pro-inflammatory signaling cascades. For example,
treatment of macrophage cell lines with non-toxic concentrations of H2O2 resulted in
increased accumulation of nuclear NFκB and AP-1, presumably by acting as a secondary
messenger in the NFκB and MAPK signaling pathways (184, 185). Therefore, glucose-
mediated ROS production can occur as part of the typical burst associated with activation as
well as in response to metabolism in the face of excess glucose availability.
Cellular redox potential is a third mechanism that can be modified with excessive glucose
exposure, as in the case of Type 2 diabetes. When intracellular glucose concentrations
overwhelm the glycolytic pathway, glucose is instead reduced to sorbitol via the polyol
pathway (also known as the sorbitol-aldose reductase pathway) resulting in decreased
concentrations of NADPH (balanced by an increase in NADP+) and a blunting of the anti-
oxidant glutathione levels (186). The decreased NADPH availability will systemically affect
redox reactions since NADPH is a required cofactor for many of these reactions. A fourth
mechanism is one linked to TGFβ. Exposure to high concentrations of glucose result in
increased secretion of TGFβ-1 which, following receptor binding, causes the
phosphorylation of small mothers against decapentaplegic proteins (SMADS-2 and -3) that
subsequently translocate to nucleus, interact with SMAD-4 and ultimately stimulate
transcription of pro-inflammatory proteins such as PAI-1, discussed above (187, 188).
Furthermore, NADPH oxidase subunits NOX1-5, p22phox, p47phox, p67phox, and Rac1/Rac2
are all SMAD target genes displaying increased transcription rates stemming from TGFβ-1
signaling, underscoring the mechanism for the increase in NADPH oxidase activity with
increased glucose exposure. Last but certainly not least, glucose-mediated modification of
lipid metabolism and synthesis is well-characterized and should be considered as a potential
glucose-derived source of inflammatory activators. Elevated glucose uptake has been shown
to increase the pro-inflammatory eicosanoid-generating COX-2 pathway (189). In addition,
glucose can regulate lipid synthesis which contributes to production of pro-inflammatory
fatty acid, as well as obesity, through triglyceride accumulation. Glucose signals through
carbohydrate response element binding protein (ChREBP) to drive transcription of fatty acid
synthase, which produces palmitate, a saturated fatty acid that can stimulate pro-
inflammatory pathways, as detailed below (147, 190). Taken together, elevated glucose
uptake and metabolism activates multiple pathways that are linked to the inflammatory
response, including kinase and transcriptional activation, ROS production, a shift in redox
potential, TGFβ-mediated cytokine production, and synthesis of pro-inflammatory lipids
(Fig. 3).
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Adipocyte hypoxia, glucose uptake, and endoplasmic reticulum (ER) stress
While glucose may be elevated in diabetes, it is often not high in pre-diabetic or insulin
resistant patients due to compensatory β-cell proliferation and elevated secretion of insulin
leading to hyperinsulinemia. So, how are elevated glucose uptake and metabolism linked to
obesity-induced inflammation in adipose tissue? One potential mechanism is through
hypoxia-induced glucose uptake. Cellular hypoxia occurs when oxygen tension decreases to
the point that oxygen availability is not adequate to support normal cellular processes. Obese
adipose is hypoxic, in part, because of rapid adipocyte expansion, such that the diffusion
distance of oxygen is exceeded, which forces an increase in angiogenesis and tissue
remodeling in an effort to increase blood flow to the adipose tissue (191–195). To survive a
hypoxic episode, cells must adapt to the low-oxygen environment and this adaptation
includes altering gene expression patterns (193). Hypoxia-inducible factor-1 (HIF-1) is a
well-characterized transcription factor that accumulates during hypoxia (196). Increased
HIF-1 results in increased transcription of target genes involved in erythropoiesis and
angiogenesis (197). Importantly, hypoxia has been implicated in the development of adipose
inflammation and increased macrophage infiltration as well as Th17 and Treg differentiation
(194, 198). During hypoxia, immune cells, found in the stromal vascular fraction,
predominately macrophages, have been shown to increase pro-inflammatory cytokine
production (191) (Fig. 1B). Of particular interest for this review, it has been reported that
adipose hypoxia causes an induction of macrophage GLUT1 expression through up-
regulation of HIF-1-mediated gene transcription (199). Importantly, GLUT1 expression was
not increased in muscle, indicating that the hypoxic effect was local and adipose-specific
rather than systemic.
In addition, another mechanism up-regulating glucose metabolism is one linked to the
endoplasmic reticulum (ER). Secreted and membrane proteins are generated and folded in
the ER and membrane lipid synthesis also occurs here. The ER is sensitive to shifts in
cellular homeostasis brought about in response to hypoxia, obesity, and altered nutrient
availability including glucose and lipids such as palmitate and cholesterol (200). Hypoxia is
linked to ER stress because it results in an accumulation of misfolded proteins within the
ER, thus initiating the unfolded protein response (UPR) in an effort to cope and, at the same
time, increasing HIF-1 accumulation and driving increased GLUT1 expression (201, 202).
Importantly, ER stress is activated in the adipose of obese mice, and Ozcan et al. (200, 203,
204) demonstrated that chronic ER stress drives obesity-induced inflammation and that
blunting ER stress with genetic means or pharmacologically blunts insulin resistance.
Lipotoxicity and obesity-induced inflammation
Lipotoxicity is the state of lipid stress associated with elevated lipid content and ectopic
lipid storage in tissues, such as liver and muscle, which can be chronic or acute. Obesity,
persistent post-prandial lipoprotein circulation, weight loss, and fasting are conditions which
result in an elevation of circulating levels of NEFA and, subsequently, an increase in
inflammation (205–208). Macrophages take up VLDL and LDL, and Hasty et al. (209)
demonstrated that VLDL loading of macrophages induces lipid storage and consequent
inflammatory response. In addition to lipoprotein delivery, adipose is a likely source of fatty
acids and, in fact, adipocytes may be the primary lipid source for macrophages found in this
tissue (210, 211). Fatty acids can be derived from several sources, all known to be elevated
in the obese state: (i) NEFA in serum; (ii) lipoprotein lipase (LPL) action on very low-
density lipoproteins (VLDL) and chylomicron particles (212, 213); (iii) lipase action on
triglyceride droplets in adipose (214); (iv) de novo lipogenesis, and/or (v) phagocytosis of
apoptotic adipocytes (15, 23).
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Fatty acids likely enter the macrophage through plasma membrane fatty acid transporters
such as CD36, also known as fatty acid translocase (FAT) (215), which has been shown to
play a role in the pro-inflammatory response in adipose (216). CD36 expression is elevated
in macrophages isolated from obese animals and is induced when insulin signaling is
dysregulated by insulin receptor deficiency (217, 218). Cytosolic lipid transporters, namely
fatty acid-binding proteins, are also central to obesity and inflammation (26, 37, 140, 219,
220). Fatty acid-binding proteins are expressed in macrophages and play a major role in
fatty acid and cholesterol metabolism (26, 37, 140, 219–221). Consequently, fatty acid
transporters and binding proteins in adipose macrophages play critical roles in the immune
response, serving as a link between fatty acid metabolism and inflammation in the context of
obesity. Once inside the macrophage, however, little is known about the partitioning of
NEFA either toward oxidation, triacylglyceride synthesis, or conversion into signaling lipid
mediators and this remains an area of intense investigation.
Fatty acid signaling, metabolism, and ER stress
Increased circulating or intracellular NEFA possess the ability to modulate inflammation
through several fatty acid-sensing mechanisms including cellular membrane receptors such
as TLRs and G-protein coupled receptors (GPRs), and by serving as ligands for transcription
factors such as the peroxisome proliferator activated receptor family (PPARsα, γ, δ). In
addition, metabolism of fatty acids can result in release of oxidation intermediates called
acylcarnitines or promote the generation of ROS through mitochondrial electron transport
chain activity. Finally, fatty acids can be converted into bioactive lipid mediators such as
eicosanoids, DAG, and ceramides, well-known modulators of inflammation through
subsequent activation of signaling cascades including IKK, PKC, or the inflammasome,
detailed in the following discussion.
The specific fatty acid species and the relative ratio of particular fatty acids found within the
microenvironment are two highly relevant mediators of the inflammatory response.
Saturated fatty acids, particularly stearic, lauric, and palmitic acid, activate TLR2 and TLR4
and drive the pro-inflammatory response by activation of the NFκB pathway, leading to
increased expression of pro-inflammatory target genes (147, 222) and prostaglandins via an
increase of COX-2 expression and activity in monocytes (190). In contrast, unsaturated fatty
acids blunt induction of COX-2 and NFκB target genes (190, 222, 223). Second, GPRs such
as GPR40, 41, 43, 84, 119, and 120 are receptors for some fatty acids (224, 225). For
example, iGPR120, an omega-3 fatty acid receptor on expressed on macrophages, plays a
role in blunting M1 macrophage activation and enhances gene expression patterns typical of
M2 macrophages (226, 227). Therefore, not only is the fatty acid milieu relevant to the
inflammatory response, but also the pattern of TLRs and GPRs that fatty acids can signal
through are highly significant. In summary, the inflammatory response to fatty acids
suggests that modifying consumption of different types of dietary fat may help modulate
several of the inflammatory pathways discussed here.
An additional mechanism by which lipotoxicity leads to inflammation is through defective
β-oxidation. Excessive levels of NEFA, as characteristic of obesity, will force an increase in
mitochondrial β-oxidation – the process by which fatty acids are hydrolyzed to generate
ATP – simply by increased delivery of substrate. Excess accumulation of lipids in tissues,
i.e. lipotoxicity, however, can overwhelm the capacity of mitochondria to fully catabolize
fatty acid substrate, resulting in incomplete β-oxidation. This phenomenon occurs when
mitochondrial uptake of fatty acids exceeds the need for ATP production (228). With fatty
acid overload, β-oxidation is highly elevated, as is gene expression for enzymes in this
pathway; however, genes for the tricarboxcylic acid cycle (TCA) remain unaltered and are
therefore hindered in their capacity to accept the acetyl-coA generated via β-oxidation. This
typically occurs when there is limited drive for increased production of ATP, as in the obese
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state (228). Apparent overload of the β-oxidative pathway leads to production and
accumulation of partially oxidized lipid byproducts including acylcarnitines, eventually leak
from tissues (229). Importantly, increased serum and muscle acylcarnitines are detected
during insulin resistant episodes, including fasting, persistent ingestion of a high fat diet, and
obesity (228–233). Conversely, the inverse correlation is observed in models of enhanced
insulin sensitivity, including during times of exercise training and in models employing
genetically mediated reversal of diet-induced insulin resistance (228, 230, 233). We and
others have shown that acylcarnitines are not only markers of defective oxidation but also
mediate the pro-inflammatory response by blunting AMPK expression similar to M1
activation and through activation of NFκB transcription (229, 234, 235). Indeed, several
epidemiological studies have linked acylcarnitine profiles with insulin resistance and other
pathologies (236). Furthermore, similar to elevated glucose metabolism, elevated NEFA
levels result in increased production of endogenous ROS through complete metabolism of
fatty acids in the electron transport chain (237, 238), which has been linked to altered insulin
responsiveness in both mice and humans (239–241). Interestingly, the saturated fatty acid
palmitate also activates NADPH oxidase and ROS production, similar to glucose and the
oxidative burst detailed above. Therefore, ROS and acylcarnitines serve as important
intermediaries between incomplete and complete β-oxidation of NEFA and elevation of
inflammatory kinase activity in macrophages.
The NLR family, pyrin domain containing 3 (NLRP3) inflammasome is another signaling
cascade that has been shown to play a critical role in insulin resistance (242–244). The
inflammasome is a multimeric complex constructed of an intracellular stress signal receptor,
typically a Nod-like receptor such as NLRP3, the cysteine protease precursor procaspase-1,
and an adapter protein apoptosis-associated speck-like protein containing a CARD (ASC)
(reviewed in detail in 243). Inflammasomes are found in cells involved in the innate immune
system and mediate the maturation and secretion of the pro-inflammatory cytokine IL-1β
and IL-18. Upon activation, procaspase-1 assembles into its catalytically active form and
cleaves pro-IL-1 β and pro-IL-18, which is followed by secretion of the cytokines by
macrophages. The binding of IL-1β to the IL-1 receptor on target cells triggers the
production and secretion of many pro-inflammatory cytokines, which, in turn, promote
further inflammation, thus IL-1β secretion initiates and sustains a progressively amplified
cytokine network (245). How is the inflammasome linked to obesity-induced inflammation?
In adipose, elevated levels of saturated fatty acids trigger inflammasome activation in
macrophages residing within this tissue, resulting in decreased AMPK activity and
mitochondrial autophagy (246). Reduced mitochondrial turnover results in an accumulation
of damaged and malfunctioning mitochondria, which directly contributes to increased ROS
production in these cells. Elevated ROS triggers the inflammasome formation culminating in
enhanced IL-1β and IL-18 secretion into the adipose microenvironment. IL-1β interaction
with adipocyte IL-1 receptor promotes disruption of the adipocyte insulin signaling
pathway, thus contributing to decreased insulin sensitivity (246). Similar to TLR activation,
saturated fatty acids, such as palmitate, but not unsaturated fatty acids have been linked to
inflammasome activation in macrophages. Ceramide, generated from sphingomyelin
degradation or the combination of long-chain fatty acids and sphingosine, and saturated fatty
acids also activate procaspase-1 and subsequent IL-1β release. In macrophages, activation of
the NLRP3 inflammasome has been shown to play a critical role in the development of
insulin resistance. Furthermore, IL-1β secretion is blunted in NLRP−/− mice, and genetic
deletion of either NLRP3, ASC, or caspase-1 leads to increased glucose tolerance and
insulin sensitivity in mice (244–249). Of note, less B and T cells are detected in adipose of
NLRP3−/− mice (245). Finally, glucose metabolism has also been demonstrated to be
essential to NLRP3-mediated inflammasome activation (250, 251). In sum, ROS,
acylcarnitine accumulation, ER stress, and the inflammasome are pathways integral to
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obesity-induced inflammation and are activated by nutrient levels, namely glucose and fatty
acids.
Links between obesity, inflammation, and human health
Chronic diseases
The overlap of obesity and chronic disease incidence is well-documented. Perhaps the best
known example of this is the link between metabolic disorders, macrophage-mediated
inflammation and atherosclerosis, which has been reviewed extensively (252, 253).
Inflammation also primes premalignant cells for cancerous transformation and plays a role
in immune surveillance during tumorigenesis. An inflamed tissue microenvironment,
perhaps similar to that described in obese individuals, offers an ideal setting for tumor onset
and progression. Indeed, the development of many cancers including esophageal, pancreatic,
colon and rectal, breast, uterine, kidney, thyroid, and gallbladder are associated with obesity
(http://www.cancer.gov/cancertopics/factsheet/Risk/obesity). Tumor initiation is supported
and promoted by increased oxidative stress stemming from activation of pro-inflammatory
immune cells (reviewed in 254). Continuous secretion of pro-inflammatory cytokines by
activated immune cells not only sustains ROS production but also can elicit epigenetic
changes in pre-malignant cells stemming from aberrant DNA methylation-driven and
microRNA-mediated gene silencing, particularly in tumor suppressor genes (255). In
addition, the cytokines produced by activated immune cells can promote the reversion of
premalignant cells to a progenitor cell-like phenotype, thus serving to expand the pool of
stem cells within tissues that may be more susceptible to damaging inflammation (254).
Once premalignant cells have been transformed and tumor formation has been initiated,
immune cells that infiltrate the tumor produce cytokines that activate transcription factors
involved in cell cycling regulation, proliferation, and survival. Interestingly, NFκB is among
the group of transcription factors upregulated during tumor promotion processes (256),
suggesting that the low-grade inflammation and cytokine production associated with obesity
can not only self-propagate but can also lead to transformation of pre-cancerous cells by
modulating expression of tumor suppressor and cell cycling genes. In addition, the obese
microenvironment provides nutrients such as glucose for fuel and building blocks necessary
for a metabolic advantage associated with cell proliferation and evasion of apoptosis (257).
Interestingly, in contrast to obese adipose, the proportion of M1 and M2 macrophages is
reverse: more M2 macrophages are present in tumors and it is thought that M2 cytokines
blunt the tumoricidal activity of M1 macrophages (258). Although recent work by our group
(91) has revealed that similar to adipose, macrophages in the tumor microenvironment are
more complex that simply M1 or M2 macrophages. The role of macrophages and other
immune cells in cancer is reviewed in detail (259, 260).
Liver disease
Non-alcoholic and alcoholic fatty liver diseases are two states also affected by obesity-
induced inflammation. Although beyond the scope of this review, the liver and resident
macrophages, called Kupffer cells, display phenotypic changes similar to adipose with
increasing triglyceride storage, lipotoxicity, glucotoxicity, and immune cell influx (reviewed
in 261). Given the extent of fatty liver disease, the role of alcohol as an additional stressor
should be considered. While some studies suggest that moderate alcohol use may be
associated with a decrease in cardiovascular events and overall mortality (262, 263), heavy
use is associated development of chronic liver disease and liver-related mortality (264, 265).
In addition, alcohol consumption was recently reported to increase the risk of breast cancer
(266). We and others have shown that alcohol is a modulator of the inflammatory response,
causing dysregulation of both innate and adaptive immunity in the liver, lung, and adipose
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(267–272, authors’ unpublished observations). Like obesity, alcohol intake results in
increased ROS production and overall levels of oxidative stress, thus promoting systemic
inflammation and tissue pathology (273, 274). Alcohol exposure also elevates circulating
concentrations of lipids, a hallmark of multiple sclerosis (MS) caused by unregulated
adipose triglyceride lipolysis (271, 275). Therefore, the interaction between the immune
response, obesity, and insults such as alcohol intake are relationships to be further identified.
Obesity and infection susceptibility
It is well-known that obese individuals have impaired immune defenses and are more
susceptible to infections (11, 276). Despite heightened inflammatory responses in obesity,
immune surveillance is compromised (120, 121). During the 2009 influenza A/H1N1
pandemic, obesity was identified as an independent risk factor for increased influenza-
related morbidity and mortality (277, 278). A recent study in obese mice demonstrated that
lung pathology and decreased survival following influenza infection is, in part, due to
impaired M2 macrophage function (279), but little else is known about the effect of
macrophage polarization on the severity of influenza infection. Because of the significant
global burden of obesity and influenza, and the high probability that both obesity and
influenza will occur simultaneously within an individual, it is important to clarify the
underlying mechanisms linking a worse outcome in obese individuals who contract
influenza in future studies.
Summary and concluding remarks
Obesity is an insidious disease correlated with multi-organ damage and increased
susceptibility to a host of diseases including metabolic disorders, cardiovascular disease,
cancer onset and progression, and infections such as influenza. Obesity is a state of low-
grade, chronic inflammation associated with alterations in immune cell populations,
including dynamic fluxes in the number and types of cells found within the inflamed tissue.
Immune cells have been shown to infiltrate adipose at the onset of weight gain; these cells
directly contribute to continued weight gain, persistent adipose inflammation, and systemic
insulin resistance.
A spectrum of macrophage phenotypes exist ranging from the pro-inflammatory, classically
activated M1 subtype to the anti-inflammatory, alternatively activated M2 subtype. In lean
individuals, M2 macrophages are dispersed throughout adipose tissue, where they produce
IL-10, IL-1 receptor antagonist, and express arginase-1 for collagen synthesis, which is
necessary for tissue remodeling and repair. At the onset of obesity and as weight gain
progresses, a shift in macrophage subtype occurs such that the M1 subtype becomes
dominant resulting in propagation of inflammation by continued production of mediators
such as TNFα, IL-1β, MCP-1, PAI-1, and ROS. M1 macrophages form crown-like
structures surrounding dying adipocytes and M2 macrophages support, while M1
macrophages disrupt insulin sensitivity in adipose and liver. Similar alterations occur with
other immune cells including influx of neutrophils, mast, CD4+ Th1, and NK cells and a
concomitant loss of insulin sensitizing cells, Th2 cells, Tregs, and eosinophils.
It is well-established that losing 10% of body weight causes dramatic improvements in MS
(280). While the most effective means for ameliorating metabolic abnormalities associated
with obesity is weight loss, treatment with anti-inflammatory medications may also be
beneficial. Stanley et al. (281) reported that administration of the TNFα signaling disruptor
etanercept (Enbrel®) improved insulin sensitivity and plasma inflammation markers in a
randomized controlled trial involving 40 obese individuals suffering from MS. These results
were corroborated by other studies (282, 283). In addition, blockade of IL-1β signaling in
individuals with Type 2 diabetes through the use of anakinra, a recombinant IL-1 receptor
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antagonist, resulted in decreased blood glucose concentrations, improved pancreatic β cell
function, and reduced circulating inflammatory markers (284). Hence, developing
therapeutic interventions aimed at converting M1-polarized macrophages to the protective
M2 subtype may be beneficial to millions of individuals worldwide who already suffer from
overweight and obesity. We suggest that targeting substrate metabolism uniquely activated
in pro-inflammatory immune cells or by shifting availability of substrate or receptors,
manipulation of the inflammatory response is an attractive approach to control obesity-
induced inflammation and insulin resistance.
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Fig. 1. Mechanisms of inflammation-induced insulin resistance
(A). Insulin signaling is initiated via binding of insulin to the insulin receptor (IR) inducing
autophosphorylation of tyrosine residues on intracellular domains, as shown on an insulin-
responsive adipocyte. The activated IR subsequently phosphorylates tyrosine residues on a
variety of substrates including the insulin receptor substrate (IRS) family of proteins and Shc
isoforms. IRS interacts with various effector molecules such as phosphatidylinositol 3-
kinase (PI3K). Simplified, PI3K phosphorylation of membrane phospholipids ultimately
leads to recruitment and activation of several kinases such as protein kinase B/Akt and
atypical protein kinase C (aPKC). Akt and aPCK are serine/threonine kinases that stimulate
membrane translocation of GLUT4 from intracellular vesicles. GLUT4 accumulation at the
plasma membrane allows insulin responsive uptake of glucose and reduces circulating
glucose levels in the fed state. (B). As the adipose depot expands in size, a variety of cell
populations begin to exhibit an inflamed or stressed state through various mechanisms
including hypoxia, release of pro-inflammatory non-esterified fatty acids, elevated reactive
oxygen species (ROS) production, and cytokines, among others. Increased adipose mass and
adipocyte diameter can lead to increases (red arrow) in hypoxia. In addition, elevated levels
of circulating saturated fatty acids (FAs) in the obese states can activate Toll-like receptor
signaling (TLR) or become hydrolyzed into inflammatory bioactive lipid mediators such as
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diacylglyceride (DAG), which ultimately lead to activation of cellular stress signaling
pathways. Additionally, inflammatory cytokines, such as TNF-α, are secreted into the
microenvironment of the obese adipose, further propagating the immune response.
Accelerated energy metabolism in the face of enhanced nutrient availability (glucose and
FAs) can increase the production of ROS. The culmination of stress in an inflamed adipose
cell induced by hypoxia, fatty acids, glucose, ROS, and inflammatory cytokines results in
the transcription of inflammatory cytokines and enzymes via activation of transcription
factors, such as interferon regulatory factor 3 (IRF-3), NFκB, hypoxia-inducible factor 1
(HIF-1), and AP-1. Furthermore, the NLRP3 (NLR family, pyrin domain containing 3)
inflammasome is activated by hypoxia and is glucose-dependent. NLRP3 regulates secretion
of the inflammatory cytokine, IL-1β following cleavage of pro-IL-1β via caspase1. Taken
together, through direct effects on adipocytes or through paracrine release of mediators, such
as saturated fatty acids and cytokines, stress kinases are activated to blunt the insulin
signaling cascade. Activated IKK and JNK prevent PI3K activation by phosphorylating IRS
on inhibitory serine residues. Further, inflammatory cytokines increase SOCS3 expression,
which can interfere with IR activity. Ultimately, insulin resistance leads to impaired insulin-
dependent GLUT4 trafficking, and thus elevated levels of circulating glucose, compensatory
secretion of insulin by pancreatic beta cells and ultimately type 2 diabetes.
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Fig. 2. Immune cell trafficking in obesity
(A). In lean adipose tissue, adipocytes store triglycerides in a large unilocular droplet.
Insulin-mediated repression of lipolysis is present along with little hypoxia, absence of
inflammation, and physiologic levels of NEFA, glucose, and ROS. In lean adipose,
alternatively activated ‘M2’ macrophages are resident and their phenotype is maintained by
the presence of T-regulatory (Treg) cells, Th2 cells, and eosinophils. Lean adipose secretes
adipokines such as adiponectin, IL-4, and IL-10, which act to maintain insulin sensitivity.
(B). As obesity progresses and adipose tissue expands, hypertrophy and hyperplasia ensues:
adipocytes accumulate triglycerides and grow large, while pre-adipocytes are differentiated
to mature adipocytes. Alterations in adipokines are prognostic: leptin rises and adiponectin
falls with increasing obesity. Chemokines are released, such as MCP1, which recruit
monocytes that polarize to pro-inflammatory M1 macrophages. M1 macrophages surround
dying adipocytes in classic ‘crown-like structures’ and release many pro-inflammatory
mediators. The loss of eosinophils, Tregs, and Th2 T cells as obesity progresses is paired
with the infiltration of CD4+ Th1 cells, CD8+ T cells, NK cells, and other granulocytes such
as neutrophils, mast cells, and basophils. Elevated cytokines, such as TNFα and IL-1β,
levels of NEFA, acylcarnitines, and ROS release contribute to the pro-inflammatory
microenvironment.
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Fig. 3. Metabolism drives macrophage polarization
Macrophages subtypes exist and can be broadly categorized as pro-inflammatory M1 or
alternatively activated M2, although in vivo studies reveal that macrophage plasticity results
in a spectrum of macrophage phenotypes. M1 macrophages are polarized from precursor M0
macrophages via the classical pathway, wherein components of bacteria such as
lipopolysaccharide (LPS) and type 1 T-helper (Th1) inflammatory cytokines interferon γ
(IFNγ) and TNFα drive expression of pro-inflammatory cytokines such as TNFα. In
contrast, M2 macrophages are activated by type 2 (Th2) cytokines IL-4 and IL-13. M2
macrophages are resident in lean adipose and are thought to be involved in remodeling,
tissue repair, and maintenance of insulin sensitivity through the production and expression
of IL-10, IL-1 receptor antagonist, and arginase-1. Plasticity along the polarization spectrum
is an intensely investigated topic. M1 macrophages tend to utilize the glycolytic pathway for
energy and metabolite generation, while M2 macrophages are reliant upon β-oxidation of
fatty acids. Regulating macrophage substrate metabolism is one potential means for
manipulation of the inflammatory response.
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